Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Thomas U. Schulz"'
Autor:
Thomas U. Schulz, Sarah Zierold, Michael M. Sachse, Giulia Pesch, Dirk Tomsitz, Katharina Schilbach, Katharina C. Kähler, Lars E. French, Lucie Heinzerling
Publikováno v:
Data in Brief, Vol 45, Iss , Pp 108676- (2022)
This dataset contains demographic, clinical, and health-related quality of life (HRQoL) data from 2905 patients including 200 cancer patients after immune checkpoint inhibitor (ICI) cessation and 2705 patients with a wide variety of autoimmune diseas
Externí odkaz:
https://doaj.org/article/78d1eb25ac8243588e14a21f302ea89e
Autor:
Dirk Tomsitz, Max Schlaak, Sarah Zierold, Giulia Pesch, Thomas U. Schulz, Genoveva Müller, Christine Zecha, Lars E. French, Lucie Heinzerling
Publikováno v:
Cancers; Volume 14; Issue 13; Pages: 3282
Simple Summary Predictive markers are necessary for immune checkpoint inhibitor (ICI) therapy. The aim of our retrospective study was to investigate the relationship between the occurrence of lymphopenia under ICI and disease outcome. A total of 116
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb1a0f4c6e2a989d413313f5463f2894
https://opus4.kobv.de/opus4-fau/frontdoor/index/index/docId/19955
https://opus4.kobv.de/opus4-fau/frontdoor/index/index/docId/19955
Autor:
Thomas U. Schulz, Sarah Zierold, Michael M. Sachse, Giulia Pesch, Dirk Tomsitz, Katharina Schilbach, Katharina C. Kähler, Lars E. French, Lucie Heinzerling
Publikováno v:
European journal of cancer (Oxford, England : 1990). 176
Immune checkpoint inhibitors (ICIs) may induce persistent immune-related adverse events (irAEs). We investigated persistent irAEs and implications on patients' lives compared to non-ICI-induced autoimmune diseases (AIs).The multicentre, cross-section
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28c01cb03579df7365a240216b657307
https://pubmed.ncbi.nlm.nih.gov/36198246
https://pubmed.ncbi.nlm.nih.gov/36198246